Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Liabilities and Shareholders Equity: 2011-2024

Historic Liabilities and Shareholders Equity for RedHill Biopharma (RDHL) over the last 14 years, with Dec 2024 value amounting to $18.0 million.

  • RedHill Biopharma's Liabilities and Shareholders Equity fell 16.57% to $18.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $81.5 million, marking a year-over-year decrease of 41.35%. This contributed to the annual value of $18.0 million for FY2024, which is 21.71% down from last year.
  • Latest data reveals that RedHill Biopharma reported Liabilities and Shareholders Equity of $18.0 million as of FY2024, which was down 21.71% from $23.0 million recorded in FY2023.
  • In the past 5 years, RedHill Biopharma's Liabilities and Shareholders Equity ranged from a high of $181.2 million in FY2021 and a low of $18.0 million during FY2024.
  • Its 3-year average for Liabilities and Shareholders Equity is $66.7 million, with a median of $23.0 million in 2023.
  • In the last 5 years, RedHill Biopharma's Liabilities and Shareholders Equity skyrocketed by 143.24% in 2020 and then crashed by 85.49% in 2023.
  • RedHill Biopharma's Liabilities and Shareholders Equity (Yearly) stood at $180.2 million in 2020, then rose by 0.53% to $181.2 million in 2021, then declined by 12.32% to $158.9 million in 2022, then plummeted by 85.49% to $23.0 million in 2023, then declined by 21.71% to $18.0 million in 2024.